应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AARD Aardvark Therapeutics
交易中 08-31 12:21:59 EDT
5.70
-0.09
-1.64%
最高
5.78
最低
5.31
成交量
5.68万
今开
5.70
昨收
5.79
日振幅
8.12%
总市值
1.24亿
流通市值
6,360万
总股本
2,170万
成交额
31.92万
换手率
0.51%
流通股本
1,117万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估,并确定该项目的后续计划
美股速递 · 05-15
Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估,并确定该项目的后续计划
Aardvark Therapeutics 计划揭盲HERO与OLE研究数据,为FDA临床搁置后的前行之路提供指引
美股速递 · 05-15
Aardvark Therapeutics 计划揭盲HERO与OLE研究数据,为FDA临床搁置后的前行之路提供指引
Aardvark Therapeutics与Piper Sandler签订股权分销协议,于2026年3月23日提交SEC文件
美股速递 · 03-24
Aardvark Therapeutics与Piper Sandler签订股权分销协议,于2026年3月23日提交SEC文件
Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验;最新指引预计2026年第二季度公布
美股速递 · 03-24
Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验;最新指引预计2026年第二季度公布
Aardvark Therapeutics暂停Ard-201肥胖症项目,包括力量与体能试验;进一步指引预计2026年第二季度公布
美股速递 · 03-24
Aardvark Therapeutics暂停Ard-201肥胖症项目,包括力量与体能试验;进一步指引预计2026年第二季度公布
RBC下调Aardvark Therapeutics评级至行业平配,目标价大幅砍至6美元
美股速递 · 03-02
RBC下调Aardvark Therapeutics评级至行业平配,目标价大幅砍至6美元
Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖,给予买入评级, 目标价22.00美元。
金融界 · 2025-03-10
Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖,给予买入评级, 目标价22.00美元。
加载更多
公司概况
公司名称:
Aardvark Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Aardvark Therapeutics, Inc.于2017年5月17日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于开发新颖的小分子疗法,以激活用于治疗代谢疾病的先天稳态途径。该公司瞄准了与缓解饥饿相关的生物途径,该公司认为这些途径有可能为患者带来变革性的结果。该公司已将精力集中在开发选择性化合物上,针对与饥饿相关的情况开发苦味受体。
发行价格:
--
{"stockData":{"symbol":"AARD","market":"US","secType":"STK","nameCN":"Aardvark Therapeutics","latestPrice":5.695,"timestamp":1788193217417,"preClose":5.79,"halted":0,"volume":56795,"delay":0,"changeRate":-0.01640759930915367,"floatShares":11168300,"shares":21696893,"eps":-3.207951,"marketStatus":"交易中","change":-0.095,"latestTime":"08-31 12:21:59 EDT","open":5.7,"high":5.78,"low":5.31,"amount":319197.55515,"amplitude":0.081174,"askPrice":5.73,"askSize":75,"bidPrice":5.68,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.207951,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788206400000},"marketStatusCode":2,"adr":0,"listingDate":1739509200000,"exchange":"NASDAQ","adjPreClose":5.79,"preHourTrading":{"tag":"盘前","latestPrice":6,"preClose":5.79,"latestTime":"08:48 EDT","volume":323,"amount":1941.279742,"timestamp":1788180491861,"change":0.21,"changeRate":0.036269,"amplitude":0.170984},"postHourTrading":{"tag":"盘后","latestPrice":6.4,"preClose":5.79,"latestTime":"19:50 EDT","volume":680,"amount":4177.5036,"timestamp":1787961050763,"change":0.61,"changeRate":0.105354,"amplitude":0.105354},"volumeRatio":1.15434,"impliedVol":2.4167,"impliedVolPercentile":0.8693},"requestUrl":"/m/hq/s/AARD","defaultTab":"news","newsList":[{"id":"1189600944","title":"Aardvark Therapeutics将揭盲Ard-101的HERO与OLE试验数据以进行评估,并确定该项目的后续计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1189600944","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189600944?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:03","pubTimestamp":1778789004,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc宣布,公司将揭盲其候选药物Ard-101在HERO试验和开放标签扩展(OLE)试验中的数据,以进行全面评估。此举旨在基于这些关键临床数据,为Ard-101项目的未来发展路径做出决策。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157105953","title":"Aardvark Therapeutics 计划揭盲HERO与OLE研究数据,为FDA临床搁置后的前行之路提供指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1157105953","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157105953?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:03","pubTimestamp":1778788980,"startTime":"0","endTime":"0","summary":"在遭遇美国食品药品监督管理局(FDA)的临床搁置后,Aardvark Therapeutics 正计划揭盲其关键研究HERO与开放标签扩展(OLE)试验的数据。此举旨在深入分析现有数据,为确定公司未来的临床开发路径提供关键依据。通过审视这些未公开的详细结果,公司期望能更好地理解监管机构的关切,并据此制定出清晰、可行的后续策略,以推动其研发项目继续向前迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132251302","title":"Aardvark Therapeutics与Piper Sandler签订股权分销协议,于2026年3月23日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1132251302","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132251302?lang=zh_cn&edition=full","pubTime":"2026-03-24 18:11","pubTimestamp":1774347083,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics Inc. 已与Piper Sandler公司正式签署了一项股权分销协议。该协议的具体条款于2026年3月23日通过美国证券交易委员会(SEC)的文件对外公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146815608","title":"Aardvark Therapeutics暂停针对PWS的Ard-101三期HERO及OLE试验;最新指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1146815608","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146815608?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:23","pubTimestamp":1774297410,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics公司宣布,已暂停其候选药物Ard-101用于治疗普瑞德-威利综合征(PWS)的三期HERO临床试验及开放标签扩展(OLE)研究。\n公司表示,预计将在2026年第二季度提供关于该研发项目下一步计划的进一步指导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125745058","title":"Aardvark Therapeutics暂停Ard-201肥胖症项目,包括力量与体能试验;进一步指引预计2026年第二季度公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1125745058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125745058?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:21","pubTimestamp":1774297278,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics已决定暂停其Ard-201肥胖症治疗项目的研发进程,该项目原计划包含针对患者力量与体能改善的临床试验。公司表示,关于该项目的后续发展方向及详细计划,预计将在2026年第二季度提供进一步的明确指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103365650","title":"RBC下调Aardvark Therapeutics评级至行业平配,目标价大幅砍至6美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103365650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103365650?lang=zh_cn&edition=full","pubTime":"2026-03-02 13:52","pubTimestamp":1772430778,"startTime":"0","endTime":"0","summary":"加拿大皇家银行(RBC)宣布,将Aardvark Therapeutics的股票评级从“跑赢大盘”下调至“行业平配”,同时将其目标价从18美元大幅削减至6美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518226139","title":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖,给予买入评级, 目标价22.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518226139","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518226139?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:41","pubTimestamp":1741610495,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics(AARD.US)获B of A Securities首次覆盖,给予买入评级, 目标价22.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/10204148634837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AARD","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://aardvarktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.151},{"period":"1month","weight":0.0883},{"period":"3month","weight":0.4088},{"period":"6month","weight":-0.5364},{"period":"1year","weight":-0.318},{"period":"ytd","weight":-0.5589}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aardvark Therapeutics, Inc.于2017年5月17日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,专注于开发新颖的小分子疗法,以激活用于治疗代谢疾病的先天稳态途径。该公司瞄准了与缓解饥饿相关的生物途径,该公司认为这些途径有可能为患者带来变革性的结果。该公司已将精力集中在开发选择性化合物上,针对与饥饿相关的情况开发苦味受体。","exchange":"NASDAQ","name":"Aardvark Therapeutics","nameEN":"Aardvark Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aardvark Therapeutics,AARD,Aardvark Therapeutics股票,Aardvark Therapeutics股票老虎,Aardvark Therapeutics股票老虎国际,Aardvark Therapeutics行情,Aardvark Therapeutics股票行情,Aardvark Therapeutics股价,Aardvark Therapeutics股市,Aardvark Therapeutics股票价格,Aardvark Therapeutics股票交易,Aardvark Therapeutics股票购买,Aardvark Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aardvark Therapeutics(AARD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aardvark Therapeutics(AARD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}